Funding to support phase 2 trial of INNA-051 aimed at preventing viral respiratory infections

Early data from novel immunotherapy drug shows tumour response in resistant cancers

Global Fund welcomes private sector support ahead of phase 8 replenishment summit

Subcutaneous therapy delivers 45 percent response rate in difficult-to-treat patients

CHMP backs once-weekly subcutaneous option for systemic lupus erythematosus

Seven new technologies selected to help transform NHS care and speed up diagnosis

Designation supports phase 3 launch in watch-and-wait patients in 2026

Applied Research Collaborations to drive innovation and tackle inequalities across England

BioChaperone Lispro demonstrates improved post-meal glucose control compared to Humalog

Phase 1 and phase 2 results highlight promise of ADCs for hard-to-treat cancers